New insights into the human 5‐HT 4 receptor binding site: exploration of a hydrophobic pocket

• Published in: British journal of pharmacology Vol. 143; no. 3; pp. 361 - 370
• Main Authors: Rivail, Lucie, Giner, Mireille, Gastineau, Monique, Berthouze, Magali, Soulier, Jean‐Louis, Fischmeister, Rodolphe, Lezoualc'h, Frank, Maigret, Bernard, Sicsic, Sames, Berque‐Bestel, Isabelle
• Format: Journal Article
• Language: English
• Published: 17.02.2009
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1038/sj.bjp.0705950

A body of evidences suggests that a hydrophobic pocket of the human 5‐HT 4 receptor contributes to the high affinity of some bulky 5‐HT 4 ligands. A thorough study of this pocket was performed using mutagenesis and molecular modeling. Ligand binding or competition studies with selected bulky ligands (RS39604, RS100235, [ 3 H]GR113808 and ML11411) and small ligands (5‐HT and ML10375) were carried out on wild‐type and mutant receptors (W7.40A/F, Y7.43F, R3.28L) transiently transfected in COS‐7 cells. The functional activity of the mutated receptors was evaluated by measuring the ability of 5‐HT to stimulate adenylyl cyclase. For W7.40F mutation, no changes in the affinity of studied ligands and in the functional activity of the mutant receptor were observed, in contrary to W7.40A mutation, which abolished both binding of ligands and 5‐HT‐induced cAMP production. Mutation R3.28L revealed a totally silent receptor with a basal level of cAMP production similar to the mock control despite its ability to product cAMP in the presence of 5‐HT. Moreover, a one order loss of affinity of RS39604 and a 45‐fold increase of ML11411 affinity were observed. Mutation Y7.43F modified the affinity of GR113808, which displays a 13‐fold lower affinity for the mutant than for the wild‐type receptor. In conclusion, in the hydrophobic pocket, two polar amino acids are able to interact through hydrogen bonds with bulky ligands depending on their chemical properties. Moreover, these experimental data may validate the proposed new three‐dimensional model of the human 5‐HT 4 receptor. British Journal of Pharmacology (2004) 143 , 361–370. doi: 10.1038/sj.bjp.0705950